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CARDIOVASCULAR DISEASE RESEARCH STUDIES
CV1
LIFETIME HEALTH CARE COSTS OF OBESITY-RELATED COMORBIDITIES IN THE 
UNITED STATES, 2007-2010
Chang S, Leung MY, Carlsson NP, Colditz GA
Division of Public Health Sciences, Department of Surgery, Washington University School of 
Medicine, St. Louis, St. Louis, MO, USA
OBJECTIVES: This study analyzed lifetime healthcare costs of obesity-related 
comorbidities, including diabetes, hypertension, coronary heart disease (CHD), 
and stroke. METHODS: We used data from the National Health Interview Survey 
(NHIS), 2007-2010, and linked it to the Medical Expenditure Panel Survey to esti-
mate annual healthcare expenditures. We excluded pregnant women, cancer 
survivors, and underweight individuals. Disease risks were estimated using the 
National Health and Nutrition Examination Survey data. Mortality risks were 
estimated using the NHIS Linked Mortality Public-Use Files and predicted for 
the 2007-2010 population. Analyses were stratified by gender and controlled for 
age, race, body mass index (BMI) category, comorbidities, smoking, and insur-
ance. Complex sampling designs were adjusted for. A Markov model, populated by 
disease and mortality estimates and healthcare expenditures, was built to simu-
late lifetime healthcare expenditures for gender-race-age-BMI group subpopula-
tions. RESULTS: We included 18,763 women and 14,793 men. We use insured, 
non-smoking individuals age 40 as an example. Without obesity-related comor-
bidities, remaining lifetime healthcare costs ranged from $90,125 (normal-weight, 
non-white, non-black men) to $149,761 (obese white women). With diabetes, costs 
ranged from $124,757 (overweight, non-white, non-black men) to $207,643 (obese 
white women); with hypertension, costs ranged from $118,084 (overweight, non-
white, non-black men) to $197,343 (obese white women); with CHD, costs ranged 
from $141,753 (normal-weight, non-white, non-black men) to $225,575 (obese black 
men); with stroke, costs ranged from $107,803 (normal-weight, non-white, non-
black men) to $184,283 (obese white women). With two comorbidities, obese black 
men with hypertension and CHD had the highest costs ($274,104). With three 
comorbidities, obese white women with diabetes, hypertension, and CHD incurred 
the highest costs ($357,486). With all four comorbidities, obese white women had 
the highest costs ($432,102). CONCLUSIONS: This study suggests that obesity-
related comorbidities impose a significant economic burden. Some subpopula-
tions, e.g., obese white women and obese black men, incur higher healthcare 
costs than others.
CV2
THE ASSOCIATION BETWEEN ADHERENCE TO CARDIOVASCULAR MEDICATIONS 
AND HEALTH CARE UTILIZATION
Simon-Tuval T1, Triki N2, Chodick G3, Greenberg D1
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Maccabi Healthcare Services, Tel-Aviv, 
Israel, 3Maccabi Healthcare Services and Tel-Aviv University, Tel-Aviv, Israel
OBJECTIVES: Poor adherence to medications for cardiovascular disease (CVD) is 
associated with adverse health outcomes, but little is known on its impact on 
healthcare utilization (HCU). We examined whether adherence is related to a long-
term decrease in HCU. METHODS: A retrospective cohort study of 2220 patients with 
CVD enrolled in Maccabi Healthcare Services in Israel initiating CVD medication 
therapy between 2006 and 2008. Adherence was assessed by the proportion of days 
covered (PDC) with medications. Patients were defined as: non-adherent (PDC< 0.4), 
partially adherent (0.4≤ PDC< 0.8), and adherent (PDC≥ 0.8). HCU was estimated fol-
lowing treatment initiation and up to four years. Multivariable GEE models were 
used to analyze predictors of HCU. Model I included total adherence during the 
entire follow-up period as well as the interaction between this measure and the 
follow-up year. Model II included previous and current year’s adherence as well 
as previous year’s HCU cost. Both models were adjusted to potential confounders 
including: age, gender, socioeconomic status, ownership of voluntary supplemen-
tary health insurance, and comorbidities. RESULTS: The median age of patients 
was 63 (67% males). Fifty one percent of patients (n= 1139) were defined as adher-
ent, 24% as partially adherent and 25% as non-adherent. Model I: The annual HCU 
costs of adherent patients decreased in 9% following treatment initiation (RR= 0.91, 
95% confidence interval (CI): 0.88-0.95, P< 0.001). This decrease stem predominantly 
from reduction in hospitalization and medication costs. No significant changes in 
annual costs following treatment initiation were observed among partially adherent 
(RR= 0.97, 95% CI: 0.88-1.07, P= 0.526) and non-adherent (RR= 0.99, 95% CI: 0.90-1.09, 
P= 0.785) patients. Model II: No temporal association was found between adherence 
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and HCU. CONCLUSIONS: Adherence to CVD medications is suboptimal. Adherence 
is associated with long-term decrease in healthcare expenditure. Exploring reasons 
for the high non-adherence and ways to improve adherence may optimize utiliza-
tion of health systems’ scarce resources.
CV3
PREVALENCE AND DIRECT MEDICAL COSTS ASSOCIATED WITH ANGINA AND 
CHEST PAIN FOLLOWING PERCUTANEOUS CORONARY INTERVENTION IN THE 
UNITED STATES
Machacz S1, Bonafede 2, Wade S3, Stephens L1, Hernandez J1
1Abbott Vascular, Santa Clara, CA, USA, 2Truven Health Analytics, Cambridge, MA, USA, 3Wade 
Outcomes Research and Consulting, Salt Lake City, UT, USA
OBJECTIVES: Percutaneous coronary intervention (PCI) is effective in reducing 
angina and improving quality of life. However, as reported in clinical trials, angina 
and chest pain remain a clinical challenge post-PCI. Currently there is limited 
contemporary data on the real world rate and its economic burden. We sought to 
describe the incidence and direct costs associated with angina or chest pain fol-
lowing a PCI. METHODS: Patients undergoing PCI (index event) were identified in 
the Truven Health MarketScan Commercial and Medicare Supplemental Databases 
from 2008-2011. Patients were required to have 12 months of continuous enroll-
ment pre- and post-index. Post-index angina and chest pain were defined as an 
inpatient claim with a principal diagnosis of angina or chest pain, an outpatient 
claim with an angina or chest pain diagnosis with an accompanying stress test, 
repeat PCI or cardiac catheterization, more than one month post-index. Total and 
cardiovascular-specific costs were described 1-3 years post-index in 2013 US$. 
Patients with post-index acute coronary syndrome (ACS) were excluded from the 
cost analysis. RESULTS: 51,756 patients met the selection criteria (mean age: 61.8 
years, 72% male). The incidence of post-PCI angina or chest pain was 27.8% by one 
year increasing to 40.1% by three years post-PCI. Average total costs for angina/chest 
pain patients were 1.8 times higher (+$14,514) than those without angina, chest pain 
or ACS (p< 0.001) with differences persisting at three years (p< 0.001). Post-PCI cardi-
ovascular-related costs were likewise higher for angina/chest pain patients one year 
($18,548 (SD= $30,525) versus $7,896 (SD= $17,638), p< 0.001) and three years post-
index ($33,238 (SD= $43,261) versus $19,773 (SD= $34,097), p< 0.001). CONCLUSIONS: 
Post- PCI angina and chest pain are common and carry substantial direct medical 
burden. Strategies to reduce these events could impact the costs and improve out-
comes of ischemic heart disease.
CV4
OUTCOMES AND HEALTH RESOURCE UTILIZATION AMONG PATIENTS WITH 
HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) AT AN ACADEMIC 
MEDICAL CENTER (AMC) IN THE UNITED STATES
Bress A1, King J1, Singhal M1, Brixner D1, Kielhorn A2, Patel H2, Maya J2, Biskupiak JE1, 
Munger M1
1University of Utah, Salt Lake City, UT, USA, 2Amgen, Thousand Oaks, CA, USA
OBJECTIVES: To assess clinical characteristics, hospitalizations, and hos-
pitalization charges among a contemporary, real world cohort of HFrEF 
patients. METHODS: A retrospective cohort study of HFrEF, identified by ICD-9 
code 428.x with a left ventricular ejection fraction (LVEF) ≤ 40% between 01/01/08 
to 12/31/13 (study period) were identified using an AMC enterprise data warehouse 
(EDW) that includes electronic health records and billing/administrative claims. 
Demographic, clinical, and hospitalization/charge data were extracted. The index 
date was defined as the first mention of an ICD-9 of 428.x within the study period. 
A subset of prevalent HFrEF underwent chart review to obtain detailed medica-
tion and medical histories. RESULTS: The cohort comprised 1931 HFrEF with a 
mean age of 63±15 years, prevalently Caucasian (70%) males (70%). The average 
LVEF was 28±9%. Medication data and etiology was assessed in prevalent HFrEF 
(n= 989). The prevalent HFrEF cohort was predominantly ischemic etiology (67%) 
and ACEi/ARB/aldosterone antagonists were prescribed in 53%/16%/29%, respec-
tively. Eighty percent were on β -adrenergic blockers. Atrial fibrillation and renal 
insufficiency were present in 45% and 42%, respectively. Devices were present in 
34% (Implantable Cardioverter-Defibrillator) and 16% (Cardiac Resynchronization 
Therapy) of patients. In the full sample, during a mean follow up period of 34±26 
months, all-cause mortality was 18% (13% CV death) at one-year and 23% (16% 
CV death) at two-years. There were 2106 all-cause hospitalizations of which 972 
(46%) were for heart failure (HF). The median length of stay for HF hospitaliza-
tions was 4.3 days and the median charge was $27,230. Among the HF hospitali-
zations 30-day readmission rates were 167 (21%) for all-cause, and 111 (13%) for 
HF. CONCLUSIONS: In an AMC-based EDW, HFrEF was well treated, resulting in 
a 1-year mortality and 30-day re-admission rates similar to published data. The 
median charge for a HF hospital stay was $27,230.
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M1 and 36.1%-46.6% of M2 received second line while 25.6%-32.3% of M1 and 18.2%-
25.1% of M2 received third line. Increasing the gap to 60 days decreased the total rate 
of second line therapy slightly for M1 patients to 43.0%-51.3% and to 33.0%-45.1% 
for M2. The rate of third-line therapy was similarly lower at 23.0%-30.0% for M1 
patients and 17.3%-23.2% for M2. Increasing from a 60-day to 90-day gap resulted 
in an absolute decline in the 60-day rate of therapy of 0.8%-2.6% in second line and 
0.3%-3.1% in third line across both the M1/M2 groups. CONCLUSIONS: The data are 
in agreement between the 2 databases, and analysis by varying treatment gaps did 
not significantly impact results.
DB4
DEVELOPMENT AND VALIDATION OF ALGORITHMS TO IDENTIFY STATIN 
INTOLERANCE IN A US ADMINISTRATIVE DATABASE
Foody JM1, Lamerato L2, Dalal M3, Sung JC3, Khan I3, Jhaveri M3, Koren A3, Schulman KL4
1Harvard Medical School, Boston, MA, USA, 2Henry Ford Health System, Detroit, MI, USA, 3Sanofi 
US, Inc., Bridgewater, NJ, USA, 4Outcomes Research Solutions, Inc., Bolton, MA, USA
OBJECTIVES: Develop and validate an algorithm to define statin intolerance (SI) 
in an administrative database (AD). METHODS: Adults with ≥ 1 qualifying change 
in statin therapy and ≥ 1 prior diagnosis of hyperlipidemia, hypercholesterolemia, 
or mixed dyslipidemia were identified from the AD of the Health Alliance Plan 
at Henry Ford Health System (HFHS). A sample of 1000 patients was drawn from 
the pool of eligible adults using an 80/20 ratio of patients taking a moderate- to 
low-intensity statin or a high-intensity statin at the time of qualifying change in 
therapy. Statin utilization and adverse events data were abstracted from the AD 
and the HFHS electronic medical record (EMR). Patients were stratified by high 
or low cardiovascular risk based on comorbidities, and any SI was categorized as 
absolute (AI) or titration (TI). In both the AD and the EMR, identification of SI was 
based on statin treatment patterns and potential statin-related adverse events. 
With EMR as the reference, measures of concordance (Cohen’s kappa [κ ]) and 
accuracy (sensitivity, specificity, positive predictive value [PPV]) were reported for 
AD algorithms. RESULTS: In the sample population (n= 990), any SI was identified 
in 11.5% and 14.0%, AI in 2.2% and 3.1%, and TI in 9.7% and 11.8% of patients in the 
EMR and the AD, respectively. The algorithm identifying any SI had substantial 
concordance (κ= 0.66) and good sensitivity (78.1%), but modest PPV (64.0%). The 
TI algorithm performed better (κ = 0.74, sensitivity= 85.4%, PPV= 70.1%) than the 
AI algorithm (κ = 0.40, sensitivity= 50.0%, PPV= 35.5%). Specificity was high (> 94%) 
across all 3 algorithms. In the high cardiovascular risk cohort (n= 353), the any SI 
algorithm demonstrated robust concordance (κ = 0.73) and good sensitivity (80.9%) 
and PPV (75.3%), all of which were even higher for TI. CONCLUSIONS: A conserva-
tive but comprehensive, easily implementable, and valid SI algorithm from an AD 
is available for real-world research.
HEALTH CARE MANAGEMENT STUDIES
HM1
UTILIZATION OF ANTIDIABETICS AFTER FDA SAFETY ANNOUNCEMENTS
Ding Y.1, Gascue L.1, Lu Y.2, Ning N.1, Joyce G.1
1University of Southern California, Los Angeles, CA, USA, 2Harbor-UCLA Medical Center, Torrance, 
CA, USA
OBJECTIVES: FDA-issued safety alerts and warnings play a vital role in post-mar-
ket drug surveillance. We examine the effects of the FDA safety announcements 
for rosiglitazone and pioglitazone on the utilization of these drugs and other oral 
antidiabetics. METHODS: We link safety announcements from the FDA MedWatch 
database to Medicare drug claims (Parts D & B) from 2006 to 2010. We examine the 
timing, direction and level of demand responses to safety announcements, and 
how they differ by patients’ race/ethnicity, socioeconomic status and plan type 
(PDP vs MA-PD). We then estimate the fraction of patients that continue using an 
“alerted” medication, switch to another oral antidiabetic, or stop use altogether 
(without adding another oral medication), and how these responses differ by patient 
group and plan type. RESULTS: The demand for rosiglitazone plummeted after the 
second safety alert (in May 2007), and decreased further after a (black box) warning 
was issued (in August). After the alert, 27% to 28% of rosiglitazone users switched 
to another oral antidiabetic (predominantly pioglitazone) within 6 months of the 
alert depending on patient groups and plan type; 28% to 33% discontinued use 
of rosiglitazone, but did not add another oral antidiabetic; 38% to 44% continued 
using rosiglitazone. After the warning, the numbers were 17% to 19%, 30% to 32% 
and 49% to 52% respectively. Discontinuation rates were slightly higher among 
Hispanics (32%) and those in MA-PD plans (32%). In contrast, the demand response 
for pioglitazone was more muted, while it increased slightly after the warning (in 
August). CONCLUSIONS: The demand response to safety warnings for rosiglita-
zone was large and abrupt, and a substantial fraction of those who stopped did not 
replace it with another oral antidiabetic. The demand response was fairly constant 
across race/ethnicity, socioeconomic status, and plan type, although large responses 
raise concern about adverse health consequences.
HM2
DIFFERENCES IN MASTECTOMY RATES BASED ON HORMONE RECEPTOR 
STATUS IN EARLY STAGE TUMORS: A SEER DATABASE ANALYSIS
Hinyard L., Schwartz T.
Saint Louis University, St. Louis, MO, USA
OBJECTIVES: Breast cancer molecular subtypes provide important prognostic infor-
mation that is useful for determining adjuvant treatment strategies; however, there 
is no evidence to indicate molecular subtypes should influence choice of surgical 
treatment. The purpose of this study is to investigate the rates of mastectomy (TM) 
versus lumpectomy (BCT) for each T-stage subgroup based on hormone receptor sta-
tus. METHODS: The SEER registry was queried for all females ages 15 – 85 diagnosed 
with stage T1 or T2 invasive breast cancer from 2010-2011. Patients were stratified 
by T-stage and race. Logistic regression was used within each stratum to compare 
RESEARCH ON DATABASE METHODS STUDIES
DB1
CRITICAL PROBLEMS OF CODING DATA IN HEALTH CARE: OBESITY, SMOKING, 
AND ALCOHOL USE BY METHOD OF MEASUREMENT
Al Kazzi ES1, Lau B1, Li T2, Schneider EB1, Makary MA1, Hutfless S1
1Johns Hopkins University School of Medicine, Baltimore, MD, USA, 2Johns Hopkins Bloomberg 
School of Public Health, Baltimore, MD, USA
OBJECTIVES: The measurement of healthcare is increasingly based on risk-adjusted 
outcomes derived from coded comorbidities in large datasets. However inaccurate or 
haphazard assessment of risk factors for morbidity and mortality in medical record 
codes can have tremendous implications for quality improvement and healthcare 
reform. The purpose of this study is to compare the prevalence of obesity, over-
weight, tobacco use and alcohol abuse of a large administrative dataset with a 
direct data collection survey. METHODS: We used the International Classification 
of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for four lead-
ing comorbidities in the Nationwide Inpatient Sample (NIS) to compare them with 
a direct survey in the Behavioral Risk Factor Surveillance System (BRFSS) in 2011. 
The national and state estimates and the Pearson correlation coefficient for obe-
sity, overweight, smoking and alcohol abuse between NIS and direct survey were 
calculated. RESULTS: Compared with direct participant questioning in BRFSS, NIS 
reported substantially lower prevalence of obesity, overweight, smoking and alcohol. 
The prevalence of obesity, overweight, smoking and alcohol were 27.7%, 35.8%, 20.1% 
and 18.3% in direct survey and 9.6%, 0.21%, 12.2% and 4.6% in NIS. The correlation 
between NIS and direct survey was 0.27 for obesity (p= 0.06), 0.09 for overweight 
(p= 0.55), 0.62 for smoking (p< 0.01) and 0.40 for alcohol (p< 0.01). CONCLUSIONS: 
The prevalence of obesity, tobacco smoking and alcohol abuse based on ICD-9-CM 
codes in NIS is not consistent with prevalence rates by direct questioning. Patient-
level data extraction as a part of Meaningful Use standards, rather than ICD-9-CM 
codes, would improve the accuracy of these important contributors to patient out-
comes in NIS. Ensuring accuracy of important comorbidities is critical to quality 
improvement efforts and healthcare reform policies that are based on measuring 
risk-adjusted outcomes.
DB2
A NEW METHOD FOR COUNTING HEMOPHILIA-RELATED BLEEDING EVENTS IN 
CLAIMS DATA
Shrestha A1, Eldar-Lissai A2, Wu Y1, Batt K3, Krishnan S2, Lakdawalla D4
1Precision Health Economics, Los Angeles, CA, USA, 2Biogen Idec, Cambridge, MA, USA, 3Wake 
Forest School of Medicine, Winston-Salem, NC, USA, 4University of Southern California,  
Los Angeles, CA, USA
OBJECTIVES: Hemophilia-related bleeding events are difficult to quantify. Insurance 
claims’ data may capture the information, but there is no robust methodology to 
identify these events. METHODS: Using 2004-2012 Truven Health MarketScan com-
mercial claims database (coverage of > 30 million employees in th United States), we 
evaluated males under age 65 having ≥ 1 inpatient/≥ 2 outpatient claims 30-day apart 
for hemophilia A or B (ICD-9: 286.0, 286.1), and ≥ 1 pharmacy claim for clotting factors 
VIII or IX with ≥ 12 months continuous enrollment from first hemophilia treatment 
were selected. Bleeding events were identified using ICD-9 codes for hemarthrosis, 
hematoma or other acute bleeds in inpatient/outpatient claims. Hemophilia treat-
ment guidelines recommend 1-14 day treatment depending on bleeding severity. 
We explored aggregating claims within varying time windows (1, 7, 10, and 14 days) 
to capture a single bleeding event and assessed sensitivity of the time differences 
using pairwise rank correlations. RESULTS: We identified 2,425 and 269 hemophilia 
A and B patients. Using a 7-day window, average annual bleeds ((total bleeds ÷ 
patient-months)*12) among patients with ≥ 1 bleed equaled 2.31 (range: 1-33) for 
hemophilia A and 1.92 (range: 1-18) for hemophilia B. Results were similar for a 
10-day window (hemophilia A: 2.21 (1-31), hemophilia B: 1.81 (1–14)) and 14-day 
window (hemophilia A: 2.10 (1–24), hemophilia B: 1.69 (1–12) ) ). A 1-day window 
produced somewhat higher numbers (hemophilia A: 2.99 (1-66), hemophilia B: 2.72 
(1-45)), but pairwise rank correlation remained high across the four assumptions 
(coefficients ≥ 0.99, p-values < 0.01 for both disease types). Frequencies are com-
parable to a large US-based study reporting bleeds in moderately-severe patients, 
albeit smaller than studies of severe patients. CONCLUSIONS: Claims data can 
be utilized to construct stable, robust indices of bleeding events in hemophilia 
patients, permitting reliable studies of factors influencing bleeding frequency and 
healthcare burden.
DB3
THE IMPLICATIONS OF USING A 30-, 60-, OR 90-DAY GAP IN TREATMENT TO 
SPECIFY LINES OF CARE IN GASTRIC CANCER TREATMENT
Seal B1, Shermock KM2, Asche CV3, Kreilick C1, Xia F1, Kish J4, Zagadailov EA4, Eaddy M4
1Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, 2The Johns Hopkins Medical Institutions, 
Baltimore, MD, USA, 3University of Illinois College of Medicine at Peoria, Peoria, IL, USA, 4Xcenda, 
Palm Harbor, FL, USA
OBJECTIVES: Compare changes in patterns of care and duration of therapy result-
ing from increasing the treatment gap designating a new line of therapy in meta-
static (M) gastric cancer (GaCa). METHODS: Two large integrated claims databases 
(Pharmetrics, MarketScan) spanning July 2008 to September 2012 were used to iden-
tify patients ≥ 18 years old diagnosed and treated for GaCa. Patients were required 
to be continuously enrolled for ≥ 6 months pre- and post-diagnosis. Eligible patients 
were stratified into cohorts based on the presence and timing of metastasis (M) 
diagnosis: no metastasis (NM), ≤ 120 days (M1), and ≥ 121 days (M2). Treatment gap 
intervals were varied at ≥ 30, ≥ 60 and ≥ 90 days to indicate the start of a new line of 
chemotherapy. RESULTS: There were 6,509 (3,486 NM; 1,469 M1; 654 M2) and 3,203 
(2,004 NM; 875 M1; 324 M2) patients in each of the databases meeting all inclu-
sion criteria. Comparing the 30- and 90-day gaps, mean length of treatment (days) 
increased for M1 patients from 69.8-71.0 to 83.4-84.5 in first, 55.4-56.6 to 55.7-60.3 
in second, and 56.5-59.7 to 60.1-64.9 in third line. Using a 30-day gap, 46.4%-54.2% of 
